Systematic literature review of trials assessing recommended systemic treatments in hepatocellular carcinoma.

ABSTRACT:

Aim

To identify and evaluate the similarity of all trials assessing recommended treatments for advanced hepatocellular carcinoma.

Materials & methods

Single arm and randomized trials from any phase and published any time up to February 2021 were systematically searched.

Results

From 5677 records reviewed, 50 trials were included in the review, and 24 for assessed for similarity. In the first-line (1L) setting, several trials assessing sorafenib were noted for enrolling patients with more severe disease and/or performance status than other 1L trials; trials within the second-line (2L) setting were generally similar. Median survival was <2 years in all trial arms.

Conclusions

Trials assessing recommended treatments are largely similar and appropriate for quantita

SUBMITTER: Ronnebaum S 

PROVIDER: S-EPMC8577513 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature